Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge

We recently published 10 Stocks on Euphoria. Are You Holding Any? Liquidia Corp. (NASDAQ:LQDA) is one of the best-performing stocks on Tuesday.

Liquidia rallied for a third straight day on Tuesday, ending 13.68 percent higher at $24.10 as investor sentiment was bolstered by the higher prescription rate for its newly approved pulmonary hypertension treatment, shunning a dismal earnings performance in the second quarter of the year.

In an updated report, Liquidia Corp. (NASDAQ:LQDA) said its Yutrepia treatment, which was approved by the Food and Drug Administration (FDA) last May and was commercially launched in the first week of June, already registered as many as 900 unique patient prescriptions.

“The second quarter was a defining period for Liquidia with the FDA approval and rapid commercial launch of YUTREPIA inhalation powder. More than 350 physicians across the country have already prescribed YUTREPIA to treat patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), including those new to prostacyclin treatment or transitioning from Tyvaso, Tyvaso DPI, and even from oral prostacyclins,” said Liquidia Corp. (NASDAQ:LQDA) CEO Roger Jeffs.

In other news, Liquidia Corp. (NASDAQ:LQDA) saw a 44.7-percent wider net loss in the second quarter of the year at $41.6 million versus $28.67 million in the same period last year.

Revenues expanded by 144 percent to $8.8 million from $3.6 million in the same comparable period.

While we acknowledge the potential of LQDA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.